Parathyroid hormone (1-34) augments spinal fusion, fusion mass volume, and fusion mass quality in a rabbit spinal fusion model

Spine

Volumn 34, Issue 2, 2009, Pages 121-130

  O'Loughlin, Padhraig F ^a   Cunningham, Matthew E ^a   Bukata, Susan V ^b   Tomin, Emre ^a   Poynton, Ashley R ^c   Doty, Stephen B ^a   Sama, Andrew A ^a   Lane, Joseph M ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Adjunctive agent; Posterolateral spinal fusion; PTH; Rabbit model

Indexed keywords

PARATHYROID HORMONE[1-34]; PARATHYROID HORMONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTHRODESIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG MECHANISM; EXPERIMENTAL RABBIT; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PALPATION; PRIORITY JOURNAL; SCORING SYSTEM; SPINE FUSION; SPINE RADIOGRAPHY; ANIMAL; BONE DEVELOPMENT; BONE REGENERATION; CONVALESCENCE; DISEASE MODEL; DRUG EFFECT; LUMBAR VERTEBRA; METHODOLOGY; PHYSIOLOGY; PSEUDARTHROSIS; RABBIT; TREATMENT OUTCOME; WOUND HEALING;

ANIMALS; BONE REGENERATION; DISEASE MODELS, ANIMAL; LUMBAR VERTEBRAE; MALE; OSTEOGENESIS; PARATHYROID HORMONE; PSEUDARTHROSIS; RABBITS; RECOVERY OF FUNCTION; SPINAL FUSION; TREATMENT OUTCOME; WOUND HEALING;

EID: 64049086472     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e318191e687     Document Type: Article

References (73)

1. Kitazawa R, Imai Y, Fukase M, et al. Effects of continuous infusion of parathyroid hormone and parathyroid hormone-related peptide on rat bone in vivo: comparative study by histomorphometry. Bone Miner 1991;12:157-66.
2. Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001;16:1846 -53.
3. Rosol TJ, Capen CC, Horst RL. Effects of infusion of human parathyroid hormone-related protein-(1-40) in nude mice: histomorphometric and biochemical investigations. J Bone Miner Res 1988;3:699-706.
4. Lawrence JP, Ennis F, White AP, et al. Effect of daily parathyroid hormone (1-34) on lumbar fusion in a rat model. Spine J 2006;6:385-90.
5. Boden SD, Schimandle JH, Hutton WC. An experimental lumbar intertransverse process spinal fusion model. radiographic, histologic, and biomechanical healing characteristics. Spine 1995;20:412-20.
6. Hirano T, Burr DB, Turner CH, et al. Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 1999;14:536-45.
7. Mashiba T, Burr DB, Turner CH, et al. Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits. Bone 2001;28:538-47.
8. Frolik CA, Black EC, Cain RL, et al. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 2003;33:372-9.
9. Codrons V, Vanderbist F, Ucakar B, et al. Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1-34) from rat lungs. J Pharm Sci 2004;93:1241-52.
10. Hu Z, Niu H, Yang X, et al. Recombinant human parathyroid hormone 1-34: pharmacokinetics, tissue distribution, and excretion in rats. Int J Pharm 2006;317:144-54.
11. Jones KO, Owusu-Ababio G, Vick AM, et al. Pharmacokinetics and hepatic extraction of recombinant human parathyroid hormone, hPTH (1-34), in rat, dog, and monkey. J Pharm Sci 2006;95:2499-506.
12. Rubin MR, Bilezikian JP. Parathyroid hormone as an anabolic skeletal therapy. Drugs 2005;65:2481-98.
13. Eriksen EF, Robins DA. Teriparatide: a bone formation treatment for osteoporosis. Drugs Today (Barc) 2004;40:935-48.
14. Fraher LJ, Klein K, Marier R, et al. Comparison of the pharmacokinetics of parenteral parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in healthy young humans. J Clin Endocrinol Metab 1995;80:60-4.
15. Boden SD, Schimandle JH, Hutton WC. Lumbar intertransverse-process spinal arthrodesis with use of a bovine bone-derived osteoinductive protein: a preliminary report. J Bone Joint Surg Am 1995;77:1404-17.
16. Boden SD, Martin GJ Jr, Morone M, et al. The use of coralline hydroxyapatite with bone marrow, autogenous bone graft, or osteoinductive bone protein extract for posterolateral lumbar spine fusion. Spine 1999;24:320-27.
17. Martin GJ Jr, Boden SD, Titus L, et al. New formulations of demineralized bone matrix as a more effective graft alternative in experimental posterolateral lumbar spine arthrodesis. Spine 1999;24:637-45.
18. Morone MA, Boden SD. Experimental posterolateral lumbar spinal fusion with a demineralized bone matrix gel. Spine 1998;23:159-67.
19. Curylo LJ, Johnstone B, Petersilge CA, et al. Augmentation of spinal arthrodesis with autologous bone marrow in a rabbit posterolateral spine fusion model. Spine 1999;24:434-8; discussion 438-9.
20. Yee AJ, Bae HW, Friess D, et al. Accuracy and interobserver agreement for determinations of rabbit posterolateral spinal fusion. Spine 2004;29:1308-13.
21. Andreassen TT, Cacciafesta V. Intermittent parathyroid hormone treatment enhances guided bone regeneration in rat calvarial bone defects. J Craniofac Surg 2004;15:424-7; discussion 428-9.
22. Andreassen TT, Ejersted C, Oxlund H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 1999;14:960-8.
23. Hock JM, Gera I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 1992;7:65-72.
24. Misof BM, Roschger P, Cosman F, et al. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 2003;88:1150-6.
25. Mitlak BH, Williams DC, Bryant HU, et al. Intermittent administration of bovine PTH-(1-34) increases serum 1,25-dihydroxyvitamin D concentrations and spinal bone density in senile (23 month) rats. J Bone Miner Res 1992;7:479-84.
26. Nakazawa T, Nakajima A, Shiomi K, et al. Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing. Bone 2005;37:711-9.
27. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002;30:312-21.
28. Andreassen TT, Fledelius C, Ejersted C, et al. Increases in callus formation and mechanical strength of healing fractures in old rats treated with parathyroid hormone. Acta Orthop Scand 2001;72:304-7.
29. Bilezikian JP, Rubin MR, Finkelstein JS. Parathyroid hormone as an anabolic therapy for women and men. J Endocrinol Invest 2005;28:41-9.
30. Cranney A, Papaioannou A, Zytaruk N, et al. Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ 2006;175:52-9.
31. Dempster DW, Cosman F, Parisien M, et al. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993;14:690-709.
32. Ejersted C, Andreassen TT, Hauge EM, et al. Parathyroid hormone (1-34) increases vertebral bone mass, compressive strength, and quality in old rats. Bone 1995;17:507-11.
33. Holzer G, Majeska RJ, Lundy MW, et al. Parathyroid hormone enhances fracture healing: a preliminary report. Clin Orthop Relat Res 1999;366:258-63.
34. Jilka RL, Weinstein RS, Bellido T, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999;104:439-46.
35. Miyakoshi N. Effects of parathyroid hormone on cancellous bone mass and structure in osteoporosis. Curr Pharm Des 2004;10:2615-27.
36. Oxlund H, Ejersted C, Andreassen TT, et al. Parathyroid hormone (1-34) and (1-84) stimulate cortical bone formation both from periosteum and endosteum. Calcif Tissue Int 1993;53:394-9.
37. Rubin MR, Bilezikian JP. New anabolic therapies in osteoporosis. Endocrinol Metab Clin North Am 2003;32:285-307.
38. Rubin MR, Cosman F, Lindsay R, et al. The anabolic effects of parathyroid hormone. Osteoporos Int 2002;13:267-77.
39. Skripitz R, Andreassen TT, Aspenberg P. Strong effect of PTH (1-34) on regenerating bone: a time sequence study in rats. Acta Orthop Scand 2000;71:619-24.
40. Andreassen TT, Willick GE, Morley P, et al. Treatment with parathyroid hormone hPTH(1-34), hPTH(1-31), and monocyclic hPTH(1-31) enhances fracture strength and callus amount after withdrawal fracture strength and callus mechanical quality continue to increase. Calcif Tissue Int 2004;74:351-6.
41. Abe Y, Takahata M, Ito M, et al. Enhancement of graft bone healing by intermittent administration of human parathyroid hormone (1-34) in a rat spinal arthrodesis model. Bone 2007;41:775-85.
42. Huang RC, Khan SN, Sandhu HS, et al. Alendronate inhibits spine fusion in a rat model. Spine 2005;30:2516-22.
43. Sama AA, Khan SN, Myers ER, et al. High-dose alendronate uncouples osteoclast and osteoblast function: a study in a rat spine pseudarthrosis model. Clin Orthop Relat Res 2004;425:135-42.
44. Schimandle JH, Boden SD. Spine update: the use of animal models to study spinal fusion. Spine 1994;19:1998-2006.
45. Wolf JW Jr, White AA III, Panjabi MM, et al. Comparison of cyclic loading versus constant compression in the treatment of long-bone fractures in rabbits. J Bone Joint Surg Am 1981;63:805-10.
46. Panjabi MM, White AA III, Wolf JW Jr. A biomechanical comparison of the effects of constant and cyclic compression on fracture healing in rabbit long bones. Acta Orthop Scand 1979;50:653-61.
47. Panjabi MM, White AA III, Southwick WO. Temporal changes in the physical properties of healing fractures in rabbits. J Biomech 1977;10:689-99.
48. Friedenberg ZB, Roberts PG Jr, Didizian NH, et al. Stimulation of fracture healing by direct current in the rabbit fibula. J Bone Joint Surg Am 1971;53:1400-8.
49. Brighton CT, Krebs AG. Oxygen tension of healing fractures in the rabbit. J Bone Joint Surg Am 1972;54:323-32.
50. Zhou H, Iida-Klein A, Lu SS, et al. Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone 2003;32:513-20.
51. Iida-Klein A, Zhou H, Lu SS, et al. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. J Bone Miner Res 2002;17:808-16.
52. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349:1216-26.
53. Cosman F, Nieves J, Woelfert L, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001;16:925-31.
54. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-5.
55. Iida-Klein A, Lu SS, Cosman F, et al. Effects of cyclic versus daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity. Bone 2007;40:391-8.
56. Cosman F, Nieves J, Zion M, et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005;353:566-75.
57. Skripitz R, Andreassen TT, Aspenberg P. Parathyroid hormone (1-34) increases the density of rat cancellous bone in a bone chamber: a dose-response study. J Bone Joint Surg Br 2000;82:138-41.
58. Seebach C, Skripitz R, Andreassen TT, et al. Intermittent parathyroid hormone (1-34) enhances mechanical strength and density of new bone after distraction osteogenesis in rats. J Orthop Res 2004;22:472-8.
59. Barnes GL, Kakar S, Vora S, et al. Stimulation of fracture-healing with systemic intermittent parathyroid hormone treatment. J Bone Joint Surg Am 2008;90(suppl 1):120 -7.
60. Nakajima A, Shimoji N, Shiomi K, et al. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J Bone Miner Res 2002;17:2038-47.
61. Alkhiary YM, Gerstenfeld LC, Krall E, et al. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am 2005;87:731-41.
62. Sato M, Vahle J, Schmidt A, et al. Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH. Endocrinology 2002;143:3230-42.
63. Tashjian AH Jr, Chabner BA. Commentary on clinical safety of recombinant human parathyroid hormone (1-34) in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 2002;17:1151-61.
64. Vahle JL, Long GG, Sandusky G, et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004;32:426-38.
65. Jolette J, Wilker CE, Smith SY, et al. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol Pathol 2006;34:929-40.
66. Harper KD, Krege JH, Marcus R, et al. Osteosarcoma and teriparatide? J Bone Miner Res 2007;22:334.
67. Tashjian AH Jr, Gagel RF. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 2006;21:354-65.
68. Tsiridis E, Morgan EF, Bancroft JM, et al. Effects of OP-1 and PTH in a new experimental model for the study of metaphyseal bone healing. J Orthop Res 2007;25:1193-203.
69. Vaccaro AR, Whang PG, Patel T, et al. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year follow-up of a pilot study. Spine J 2008;8:457-65.
70. Dimar JR, Glassman SD, Burkus KJ, et al. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft. Spine 2006;31:2534-9; discussion 2540.
71. Kanayama M, Hashimoto T, Shigenobu K, et al. A prospective randomized study of posterolateral lumbar fusion using osteogenic protein-1 (OP-1) versus local autograft with ceramic bone substitute: emphasis of surgical exploration and histologic assessment. Spine 2006;31:1067-74.
72. Szpalski M, Gunzburg R. Recombinant human bone morphogenetic protein-2: a novel osteoinductive alternative to autogenous bone graft? Acta Orthop Belg 2005;71:133-48.
73. Kabasawa Y, Asahina I, Gunji A, et al. Administration of parathyroid hormone, prostaglandin E2, or 1-alpha,25-dihydroxyvitamin D3 restores the bone inductive activity of rhBMP-2 in aged rats. DNA Cell Biol 2003;22:541-6.